Efficacy and Safety Study of Cilostazol to Prevent Reoccurrence of Stroke
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
The study design is subject to relevant SFDA regulations about clinical trials. This
indication was approved in Japan in 2003.
From the end of May 2004 to the end of Dec. 2004, 720 patients with previous cerebral
infarction(see the inclusion criteria) were enrolled in to the study and received one of the
two treatment regimens, Cilostazol or Aspirin, the ratio of patient number of each group is
1:1. For each patient, the chance of entering either of these two groups is the same. The
treatment will continue till the end of 2005. During the treatment period, patients will be
observed concerning some certain events, mainly reoccurrence of stroke. If the patient
experiences reoccurrence of stroke, or other event that the doctors think it is not
appropriate to continue the study medication, this patient would stop the treatment. Patients
were also required to take MRI head scan before entering the study and on completion of the
treatment.